Overview

Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers

Status:
Completed
Trial end date:
2011-03-29
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat ascending doses of GSK2018682. The study will also provide further evidence of the potential therapeutic dose-range by measuring the inhibitory effect of GSK2018682 on Absolute Lymphocyte Counts (ALC).
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline